Table of Content
- Executive Summary
- Industry Introduction, including Taxonomy and Market Definition
- Trends and Success Factors, including Macro-economic Factors, Market Dynamics, and Recent Industry Developments
- Global Market Demand Analysis 2020 to 2024 and Forecast 2025 to 2035, including Historical Analysis and Future Projections
- Global Market Analysis 2020 to 2024 and Forecast 2025 to 2035
- By Drug Class
- By Route of Administration
- By Indication
- By Distribution Channel
- By Drug Class
- Chemotherapy Drugs
- Alkylating Agents
- Antimetabolites
- Other Drugs
- Immunomodulating Drugs
- Targeted Therapy Drugs
- Proteasome Inhibitors
- Tyrosine Kinase Inhibitors
- mTOR Inhibitors
- Others
- Hormonal Therapy
- Chemotherapy Drugs
- By Route of Administration
- Oral
- Injectable
- By Indication
- NSCLC
- Renal Cell Carcinoma
- Breast Cancer
- Prostate Cancer
- Multiple Myeloma
- Melanoma
- Lymphoma
- Leukemia
- Others
- By Distribution Channel
- Hospital Pharmacies
- Retail Pharmacies
- Specialty Clinics
- Online Pharmacies
- By Region
- Sales Forecast to 2035 by Drug Class, Route of Administration, Indication, and Distribution Channel for 30 Countries
- Competitive Assessment, Company Share Analysis by Key Players, and Competition Dashboard
- Company Profile
- AstraZeneca
- 4SC AG
- Immunocure Inc.
- Boehringer Ingelheim GmbH
- Bristol-Myers Squibb Company
- Gilead Sciences Inc.
- GlaxoSmithKline PLC
- Merck KGaA
- Hoffmann-La Roche Ltd
- Accent Therapeutics
